A U.S. death-certificate analysis found increasing overdose deaths involving broad non-benzodiazepine sedative categories and increasing co-coding with benzodiazepines over part of the study period. Those categories cannot identify a unique drug pair or quantify an individual pharmacological interaction.
What the dataset contained
The study examined 21,167 overdose deaths with T42.6 or T42.7 among multiple cause-of-death codes from 2000 through 2018. These categories include non-benzodiazepine hypnotics and gabapentinoids. The authors used trend analyses to describe changes over time, including concurrent benzodiazepine coding.
A category is broader than a molecule
The same code group can contain clinically different substances. A rise in deaths carrying a category therefore does not tell the reader that zolpidem alone increased by the same amount, or that a specific benzodiazepine combination was responsible. Multiple-cause coding also differs from a controlled measurement of the incremental risk from adding one drug.
Appropriate forensic use
The study supports attention to polysubstance involvement and cautions against assuming that substituting another sedative automatically removes risk. It does not supply the denominator of all people exposed to each combination, a measured interaction coefficient, or case-specific causation. For a death investigation, use the actual toxicology, medical history, circumstances, and cause-of-death assessment rather than translating a national coding trend into proof about one decedent.
Source and scope
This original analysis uses the supplied paper: Overdose deaths involving non BZD hypnotic sedatives in the USA Trends analyses. The interpretation above separates the authors’ findings from their implications for evidence review.
Explore related material through this site’s benzodiazepine articles and remimazolam research discussions.
Leave a Reply